Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shan Kang

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
BMC Cancer|May 10, 2023
Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factorsYanna Ye, Zhiqiang Li, Shan Kang, et al.
Frontiers in Oncology|July 5, 2021
Cohort Profile: Chinese Cervical Cancer Clinical StudyXi-Ru Zhang, Zhi-Qiang Li, Li-Xin Sun, et al.
Therapeutic Advances in Medical Oncology|February 19, 2026
Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trialYuanming Shen, Nalan Tu, Beihua Kong, et al.
Molecular Cancer Therapeutics|July 5, 2021
Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter StudyHong Zheng, Yunong Gao, Hongyan Guo, et al.
Gynecologic Oncology|October 24, 2024
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancerGuiling Li, Xiaofan Li, Rutie Yin, et al.
Cell Discovery|December 21, 2021
Genome-wide association and functional interrogation identified a variant at 3p26.1 modulating ovarian cancer survival among Chinese womenHongji Dai, Xinlei Chu, Qian Liang, et al.
Journal of Ovarian Research|December 17, 2025
A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC)Li Wang, Lingling Xie, Qingshui Li, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
BMC Cancer|May 10, 2023
Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factorsYanna Ye, Zhiqiang Li, Shan Kang, et al.
Frontiers in Oncology|July 5, 2021
Cohort Profile: Chinese Cervical Cancer Clinical StudyXi-Ru Zhang, Zhi-Qiang Li, Li-Xin Sun, et al.
Therapeutic Advances in Medical Oncology|February 19, 2026
Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trialYuanming Shen, Nalan Tu, Beihua Kong, et al.
Molecular Cancer Therapeutics|July 5, 2021
Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter StudyHong Zheng, Yunong Gao, Hongyan Guo, et al.
Gynecologic Oncology|October 24, 2024
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancerGuiling Li, Xiaofan Li, Rutie Yin, et al.
Cell Discovery|December 21, 2021
Genome-wide association and functional interrogation identified a variant at 3p26.1 modulating ovarian cancer survival among Chinese womenHongji Dai, Xinlei Chu, Qian Liang, et al.
Journal of Ovarian Research|December 17, 2025
A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC)Li Wang, Lingling Xie, Qingshui Li, et al.
Pageof 14